High‐level expression of ARID1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy

Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Her...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Cell Mol Med
Autors principals: Lin, Yuan‐Feng, Tseng, Ing‐Jy, Kuo, Chih‐Jung, Lin, Hui‐Yu, Chiu, I‐Jen, Chiu, Hui‐Wen
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5867090/
https://ncbi.nlm.nih.gov/pubmed/29392887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.13551
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars